Two Sigma Advisers’s Tectonic Therapeutic TECX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-13,071
Closed -$215K 2564
2024
Q2
$215K Sell
13,071
-11,621
-47% -$186K ﹤0.01% 2185
2024
Q1
$379K Buy
24,692
+2,600
+12% +$41.2K ﹤0.01% 1982
2023
Q4
$361K Buy
22,092
+2,375
+12% +$40.8K ﹤0.01% 2044
2023
Q3
$364K Sell
19,717
-1,716
-8% -$30.3K ﹤0.01% 1912
2023
Q2
$244K Sell
21,433
-6,242
-23% -$70.6K ﹤0.01% 2046
2023
Q1
$332K Sell
27,675
-808
-3% -$11.3K ﹤0.01% 2105
2022
Q4
$244K Sell
28,483
-4,200
-13% -$37K ﹤0.01% 2128
2022
Q3
$252K Sell
32,683
-14,650
-31% -$163K ﹤0.01% 2127
2022
Q2
$523K Sell
47,333
-8,984
-16% -$106K ﹤0.01% 1901
2022
Q1
$892K Buy
56,317
+21,834
+63% +$451K ﹤0.01% 1688
2021
Q4
$1.59M Buy
34,483
+10,708
+45% +$615K ﹤0.01% 1306
2021
Q3
$1.59M Buy
23,775
+17,325
+269% +$1.42M ﹤0.01% 1376
2021
Q2
$688K Sell
6,450
-1,333
-17% -$158K ﹤0.01% 1795
2021
Q1
$1.19M Buy
7,783
+2,991
+62% +$486K ﹤0.01% 1560
2020
Q4
$802K Buy
4,792
+3,542
+283% +$630K ﹤0.01% 1672
2020
Q3
$195K Sell
1,250
-75
-6% -$15.1K ﹤0.01% 2161
2020
Q2
$277K Buy
+1,325
New +$273K ﹤0.01% 2152

Other funds holding TECX

Two Sigma Advisers's TECX Position: Q3 2024 in Review

Two Sigma Advisers sold out of Tectonic Therapeutic (TECX) in Q3 2024, closing a stake of 13,071 shares — an estimated $215K sold.

Two Sigma Advisers first reported a position in TECX in Q2 2020 and held it in 17 quarters. The position peaked at $1.59M in Q4 2021. 53 funds tracked by Wall St. Rank hold TECX as of Q3 2024.

  • Two Sigma Advisers reported no remaining Tectonic Therapeutic position as of Q3 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 13,071 Tectonic Therapeutic shares in Q3 2024, an estimated $215K.
  • Two Sigma Advisers first reported a position in Tectonic Therapeutic in Q2 2020 and held it in 17 quarters.
  • Two Sigma Advisers's Tectonic Therapeutic position peaked at $1.59M in Q4 2021.
  • 53 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q3 2024.

Based on Two Sigma Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.